Name: UMIN ID:
Unique ID issued by UMIN | UMIN000033351 |
---|---|
Receipt number | R000037897 |
Scientific Title | A Phase I study of Inotuzumab Ozogamicin as a single agent for pediatric patients in Japan with relapsed/refractory CD22-positive Acute Lymphoblastic Leukemia |
Date of disclosure of the study information | 2018/07/20 |
Last modified on | 2021/07/12 14:30:14 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2018/07/10 14:56:33 | ||
2 | Update | 2018/07/10 15:20:09 | Interventions/Control_1 |
|
3 | Update | 2018/09/18 16:56:40 | Recruitment status |
|
4 | Update | 2019/10/31 16:56:57 | Key inclusion criteria Key inclusion criteria |
|
5 | Update | 2019/10/31 17:12:31 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Institute Institute Organization Organization Address Address Tel Institutions |
|
6 | Update | 2019/10/31 17:17:36 | Email1 |
|
7 | Update | 2020/03/24 09:51:55 | Recruitment status Date of IRB Last follow-up date |
|
8 | Update | 2021/02/10 15:12:24 | UMIN ID2 |
|
9 | Update | 2021/07/12 14:30:14 | Recruitment status |